BioAtla, Inc.
BioAtla, Inc. (BCAB) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · BCAB · as of Sep 30, 2025
Ownership Breakdown
45
Institutional Holders
▲ 5 vs Q2
$9.19M
Total Inst. Value
▲ $3.98M vs Q2
1.26M
Shares Outstanding
freeFloat 84.85%
13.35M
13F Shares Held
▲ 180,111 vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
BCAB largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
ACORN CAPITAL ADVISORS, LLC biological products, (no diagnostic substances) | 4.84M | 8.26% | 8.26% | $3.34B | Nov 17, 2025 | — held |
VANGUARD GROUP INC biological products, (no diagnostic substances) | 1.95M | 3.33% | 3.33% | $1.34B | Nov 7, 2025 | ▲ 162.6K |
TANG CAPITAL MANAGEMENT LLC biological products, (no diagnostic substances) | 1.37M | 2.35% | 2.35% | $945.23M | Nov 14, 2025 | — held |
ACADIAN ASSET MANAGEMENT LLC biological products, (no diagnostic substances) | 930.5K | 1.59% | 1.59% | $638.00M | Nov 13, 2025 | ▼ 562.1K |
RENAISSANCE TECHNOLOGIES LLC biological products, (no diagnostic substances) | 800.6K | 1.37% | 1.37% | $550.75M | Nov 13, 2025 | ▲ 46.4K |
DEUTSCHE BANK AG\ biological products, (no diagnostic substances) | 525.4K | 89.80% | 89.80% | $362.49M | Nov 13, 2025 | — held |
GEODE CAPITAL MANAGEMENT, LLC biological products, (no diagnostic substances) | 495.2K | 84.65% | 84.65% | $340.73M | Nov 12, 2025 | ▲ 3.0K |
BLACKROCK, INC. biological products, (no diagnostic substances) | 480.9K | 82.20% | 82.20% | $330.83M | Nov 12, 2025 | — held |
MILLENNIUM MANAGEMENT LLC biological products, (no diagnostic substances) | 341.3K | 58.34% | 58.34% | $234.79M | Nov 14, 2025 | ▲ 341.3K |
CITADEL ADVISORS LLC biological products, (no diagnostic substances) | 274.0K | 46.84% | 46.84% | $188.51M | Nov 14, 2025 | NEW |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
14
Increased
+1.03M shares9
New Positions
first time holders5
Decreased
−913.5K shares5
Sold Out
fully exitedNet shares change (top 50)
+120.2K
+1.03M / −913.5K
Net new holders
+13
9 new / 5 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
BCAB insider trading · insider activity
Source: SEC Form 4
3
Buy transactions
4
Sell transactions
0.75
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Vasquez Christian Chief Financial Officer | Mar 11, 2026 | Tax Withhold | 175 | $0.17 | $29.575 | 10.4K | Form 4 ↗ |
Vasquez Christian Chief Financial Officer | May 31, 2026 | Tax Withhold | 82 | $3.93 | $322.26 | 10.3K | Form 4 ↗ |
SHORT JAY M PHD Chief Executive Officer | Mar 12, 2026 | Tax Withhold | 639 | $0.17 | $107.352 | 52.6K | Form 4 ↗ |
SHORT JAY M PHD Chief Executive Officer | May 31, 2026 | Tax Withhold | 259 | $3.93 | $1.0K | 52.3K | Form 4 ↗ |
Sievers Eric Chief Medical Officer | May 31, 2026 | Tax Withhold | 134 | $3.93 | $526.62 | 11.8K | Form 4 ↗ |
Sievers Eric Chief Medical Officer | Mar 11, 2026 | Tax Withhold | 360 | $0.17 | $60.84 | 11.6K | Form 4 ↗ |
Sievers Eric Chief Medical Officer | Mar 10, 2026 | Award | 240,000 | — | — | 598.7K | Form 4 ↗ |
SHORT JAY M PHD Chief Executive Officer | Mar 11, 2026 | Award | 430,000 | — | — | 2.66M | Form 4 ↗ |
Vasquez Christian Chief Financial Officer | Mar 10, 2026 | Award | 240,000 | — | — | 530.2K | Form 4 ↗ |
SHORT JAY M PHD Chief Executive Officer | Feb 28, 2026 | Tax Withhold | 7,728 | $0.25 | $1.9K | 2.23M | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
BioAtla, Inc. (BCAB) is primarily owned by institutional investors, who hold approximately 100.0% of total shares outstanding. Company insiders own approximately 15.15%, while retail and public investors account for the remaining 0.00%.
The largest institutional shareholder of BioAtla, Inc. is ACORN CAPITAL ADVISORS, LLC, holding approximately 4.84 million shares — equal to 8.26% of outstanding shares — as of September 30, 2025.
A total of 45 institutional investors currently hold BCAB stock, with a combined institutional value of approximately $9,190,012 as of the most recent 13F filing period.
Frequently asked questions
BCAB ownershipBioAtla, Inc. (BCAB) is primarily owned by institutional investors, who hold approximately 100.0% of shares. The largest shareholder is ACORN CAPITAL ADVISORS, LLC with a 8.26% stake. Company insiders hold 15.15%. Data sourced from SEC Form 13F as of September 30, 2025.